Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228424 | 0.79 | HRH4 (0.36) | HRH4HRH3 | |
| SCHEMBL607590 | 0.78 | HRH4 (0.55) | HRH4HRH3 | |
| SCHEMBL3759303 | 0.76 | HRH4 (0.38) | HRH4HRH3 | |
| SCHEMBL604048 | 0.75 | HRH4 (0.43) | HRH4HRH3 | |
| SCHEMBL3235264 | 0.74 | HRH4 (0.36) | HRH4HRH3 | |
| SCHEMBL2571096 | 0.73 | HRH4 (0.41) | HRH4HRH3 | |
| SCHEMBL606488 | 0.72 | HRH4 (0.50) | HRH4HRH3 | |
| SCHEMBL2563821 | 0.72 | HRH4 (0.50) | HRH4HRH3 | |
| SCHEMBL3228385 | 0.70 | NOS3 (0.33) | — | |
| SCHEMBL3238431 | 0.70 | KDM4E (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2010-11-25 | — | — | US | claimed |
| EP-2209775-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB Pharma, S.A. (BE) | 2010-07-28 | — | — | EP | claimed |
| WO-2009047255-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2009-04-16 | — | — | WO | claimed |
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2010-11-25 | — | — | US | disclosed |
| EP-2209775-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB Pharma, S.A. (BE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009047255-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | HRH4, HRH2, HRH3 | HRH4 1/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.